Logo image
Impersistence of depression in youth: Implications for drug study design
Journal article   Peer reviewed

Impersistence of depression in youth: Implications for drug study design

Richard P Malone, David S Bennett, Mary Anne Delaney, Muniya S Choudhury, James F Luebbert and Jacqueline Cater
Journal of clinical pharmacology, v 46(9), pp 1044-1051
Sep 2006
PMID: 16920900

Abstract

Adolescent Child Clinical Trials as Topic - methods Depression - diagnosis Depression - drug therapy Depression - physiopathology Female Humans Male Research Design Time Factors
Food and Drug Administration data show that most anti-depressant studies in youth do not show drug effect. The few positive studies used rigorous diagnostic screening procedures, suggesting major depressive disorder (MDD) may not be a persistent condition in a subgroup of youth. To investigate persistence of MDD, we serially assessed a cohort of inpatients admitted to the hospital with a clinical diagnosis of MDD. Assessments included a structured diagnostic interview, the Diagnostic Interview for Children and Adolescents-Revised (DICA-R), and measures of depressive symptomatology. Of 66 subjects (40 girls; mean age, 14.4 +/- 2.2 years), 34 (51.5%) met DICA-R criteria for MDD at the initial postadmission assessment. Of these, only 8 (23.5%) met DICA-R criteria for MDD at any subsequent assessment. Similar reductions were found on other ratings of depression. In conclusion, MDD did not persist in this sample. The findings suggest a multigated assessment procedure should be employed before randomization in antidepressant clinical trials.

Metrics

8 Record Views
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Pharmacology & Pharmacy
Logo image